Search

Displaying results 1771 - 1780 of 8170 in total
  1. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do … Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083].

  2. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Nu-propafenone
  3. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.

  4. Drug

    Cynodon dactylon pollen

    go.drugbank.com/drugs/DB10351
    Approved

    It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

  5. Drug

    Enadenotucirev

    go.drugbank.com/drugs/DB14873
    Investigational

    Enadenotucirev is under investigation in clinical trial NCT02636036 (Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors).

  6. Drug

    Uteroglobin

    go.drugbank.com/drugs/DB14880
    Investigational

    Uteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).

  7. Drug

    PF-04691502

    go.drugbank.com/drugs/DB11974
    Investigational

    PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).

  8. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. … It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances

  9. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  10. Drug

    Bilastine

    go.drugbank.com/drugs/DB11591
    Approved

    Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.